X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
dasabuvir (249) 249
index medicus (177) 177
ribavirin (168) 168
humans (154) 154
abt-450/r-ombitasvir (128) 128
hepatitis c (121) 121
hepatitis c virus (120) 120
ombitasvir (110) 110
hepatitis c, chronic - drug therapy (98) 98
sofosbuvir (98) 98
hcv (97) 97
antiviral agents - therapeutic use (94) 94
gastroenterology & hepatology (93) 93
paritaprevir (90) 90
male (87) 87
ledipasvir (81) 81
female (79) 79
ritonavir (78) 78
antiviral agents (74) 74
drug therapy, combination (71) 71
genotype (70) 70
hepatitis (70) 70
middle aged (70) 70
hepacivirus - genetics (68) 68
interferon (68) 68
cirrhosis (67) 67
pharmacology & pharmacy (56) 56
sustained virological response (54) 54
antiviral agents - administration & dosage (52) 52
aged (51) 51
liver cirrhosis (49) 49
adult (46) 46
hepatitis c - drug therapy (46) 46
hepacivirus - drug effects (44) 44
treatment outcome (44) 44
uracil - analogs & derivatives (44) 44
virus-infection (44) 44
drug therapy (41) 41
therapy (41) 41
antiviral agents - adverse effects (39) 39
infectious diseases (38) 38
genotype 1 (36) 36
health aspects (36) 36
liver (36) 36
care and treatment (35) 35
genotype 1 infection (34) 34
infection (34) 34
medicine, general & internal (34) 34
direct-acting antivirals (33) 33
infections (33) 33
analysis (31) 31
daclatasvir (30) 30
hepatitis c, chronic - virology (30) 30
carbamates - therapeutic use (29) 29
genotype & phenotype (29) 29
macrocyclic compounds - therapeutic use (29) 29
simeprevir (29) 29
anilides - therapeutic use (28) 28
macrocyclic compounds - administration & dosage (28) 28
patients (28) 28
safety (28) 28
sulfonamides - therapeutic use (28) 28
virology (28) 28
anilides - administration & dosage (27) 27
carbamates - administration & dosage (27) 27
chronic hepatitis c (27) 27
ribavirin - therapeutic use (27) 27
sustained virologic response (26) 26
treatment-experienced patients (26) 26
viruses (25) 25
abridged index medicus (24) 24
gastroenterology and hepatology (24) 24
microbiology (24) 24
ritonavir - administration & dosage (24) 24
uracil - therapeutic use (24) 24
fibrosis (23) 23
sulfonamides - administration & dosage (23) 23
virus diseases (23) 23
genotypes (22) 22
combination (21) 21
hepatitis-c (21) 21
ritonavir - therapeutic use (21) 21
young adult (21) 21
protease inhibitors (20) 20
genetic aspects (19) 19
hepatitis c, chronic - complications (19) 19
hepatitis-c virus (19) 19
internal medicine (19) 19
telaprevir (19) 19
treatment-naive patients (19) 19
uracil - administration & dosage (19) 19
drug interactions (18) 18
hepatitis c - virology (18) 18
hepatitis c, chronic - diagnosis (18) 18
medical research (18) 18
pegylated interferon (18) 18
risk factors (18) 18
aged, 80 and over (17) 17
carbamates - adverse effects (17) 17
dosage and administration (17) 17
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (255) 255
Hungarian (8) 8
German (5) 5
Korean (3) 3
Russian (3) 3
Czech (2) 2
French (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Liver International, ISSN 1478-3223, 01/2016, Volume 36, Issue S1, pp. 47 - 57
Journal Article
Antiviral Therapy, ISSN 1359-6535, 2018, Volume 23, Issue 3, pp. 211 - 217
Background: The introduction of highly potent direct-acting combination therapies for HCV have negated the role of response-guided therapy and reduced the role... 
VIRAL LOAD | INFECTIOUS DISEASES | ABT-450/R-OMBITASVIR | ASSAY | VIROLOGY | RNA | DASABUVIR | MARKER | PERFORMANCE | PHARMACOLOGY & PHARMACY
Journal Article
World journal of gastroenterology, ISSN 1007-9327, 05/2019, Volume 25, Issue 18, pp. 2229 - 2239
The hepatitis C virus (HCV) NS5A inhibitor ABT-267 (ombitasvir, OBV), the HCV NS4/4A protease inhibitor ABT-450 (paritaprevir, PTV), the CYP3A inhibitor... 
Ombitasvir | Clinical Trials Study | Ritonavir | Genotype 1 | Paritaprevir | Hepatitis C | Dasabuvir
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9954, pp. 1597 - 1605
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9986, pp. 2502 - 2509
Journal Article
NATURE REVIEWS NEPHROLOGY, ISSN 1759-5061, 01/2016, Volume 12, Issue 1, pp. 5 - 6
Treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease (CKD) can be challenging. Now, data from the phase III C-SURFER study... 
THERAPY | DIALYSIS PATIENTS | DASABUVIR | SAFETY | UROLOGY & NEPHROLOGY | HCV | RIBAVIRIN
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 150, Issue 7, pp. 1590 - 1598
Journal Article
Hepatology, ISSN 0270-9139, 09/2018, Volume 68, Issue 3, pp. 827 - 838
The impact of sustained virologic response (SVR) on mortality after direct‐acting antiviral (DAA) treatment is not well documented in patients without advanced... 
ALL-CAUSE MORTALITY | GENOTYPE 1 | INTERFERON | VIRUS-INFECTION | THERAPY | DASABUVIR | SOFOSBUVIR | CHRONIC HEPATITIS-C | RIBAVIRIN | GASTROENTEROLOGY & HEPATOLOGY | CARE | Demography | Liver diseases | Syngeneic grafts | Mortality | Hepatocellular carcinoma | Patients | Confidence intervals | Cirrhosis | Hepatitis | Allografts | Interferon | Hepatitis C | Genotypes | Liver transplantation
Journal Article
Acta Gastro-Enterologica Belgica, ISSN 1784-3227, 01/2018, Volume 81, Issue 1, pp. 9 - 13
Background : In our country, the national program for hepatitis C virus treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir was approved for... 
Cirrhosis | Adverse events | Hepatitis C virus | Ombitasvir/paritaprevir/ritonavir and dasabuvir | hepatitis C virus | cirrhosis ombitasvir/paritaprevir/ritonavir and dasabuvir | INFECTION | adverse events | OMBITASVIR | GASTROENTEROLOGY & HEPATOLOGY | HEPATITIS-C
Journal Article
CLINICAL INFECTIOUS DISEASES, ISSN 1058-4838, 06/2015, Volume 60, Issue 12, pp. 1829 - 1836